$11.7
+0.42
(+3.72%)▲
Live
5.13%
Downside
Day's Volatility :6.17%
Upside
1.1%
48.12%
Downside
52 Weeks Volatility :64.34%
Upside
31.26%
Period | Phathom Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 22.88% | 6.5% | 0.0% |
6 Months | 62.54% | 7.1% | 0.0% |
1 Year | -19.77% | 9.8% | 0.0% |
3 Years | -64.52% | 14.2% | -20.2% |
Market Capitalization | 670.8M |
Book Value | - $2.54 |
Earnings Per Share (EPS) | -4.46 |
Wall Street Target Price | 22.88 |
Profit Margin | 0.0% |
Operating Margin TTM | -3658.68% |
Return On Assets TTM | -51.75% |
Return On Equity TTM | -3489.0% |
Revenue TTM | 2.6M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -206.5M |
Diluted Eps TTM | -4.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.27 |
EPS Estimate Next Year | -3.84 |
EPS Estimate Current Quarter | -1.31 |
EPS Estimate Next Quarter | -1.27 |
What analysts predicted
Upside of 95.56%
Sell
Neutral
Buy
Phathom Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Phathom Pharmaceuticals Inc | 10.37% | 62.54% | -19.77% | -64.52% | -54.15% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Phathom Pharmaceuticals Inc | NA | NA | NA | -5.27 | -34.89 | -0.52 | NA | -2.54 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Phathom Pharmaceuticals Inc | Buy | $670.8M | -54.15% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Phathom Pharmaceuticals Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 81.4%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 251.0%
Medicxi Ventures Management (Jersey) Ltd
The Carlyle Group Inc
Amvescap Plc.
BlackRock Inc
Ensign Peak Advisors Inc
Vanguard Group Inc
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Organization | Phathom Pharmaceuticals Inc |
Employees | 452 |
CEO | Ms. Terrie J. Curran |
Industry | Health Technology |
A Spac I Acquisition Corp
$11.70
+3.72%
Keyarch Acquisition Corp
$11.70
+3.72%
Connexa Sports Technologies Inc
$11.70
+3.72%
Us Value Etf
$11.70
+3.72%
First Wave Biopharma Inc
$11.70
+3.72%
Global X Msci Next Emerging
$11.70
+3.72%
Fat Projects Acquisition Corp
$11.70
+3.72%
Capital Link Global Fintech
$11.70
+3.72%
Applied Uv Inc
$11.70
+3.72%